Gene and Cell Therapy
A section of Pharmaceutics (ISSN 1999-4923).
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- Mesenchymal Stromal Cell-Based Cell Therapy: Recent Advances and Expectations (Deadline: 10 December 2024)
- Delivery of Oligonucleotide Therapeutics (Deadline: 20 December 2024)
- Plasmid DNA for Gene Therapy and DNA Vaccine Applications, 2nd Edition (Deadline: 31 December 2024)
- mRNA Therapeutics for Cancer Treatment (Deadline: 31 December 2024)
- MicroRNAs in Cancer Therapy: Recent Advances and Prospects (Deadline: 20 January 2025)
- Targeted Delivery of Genes (Deadline: 20 January 2025)
- Extracellular Vesicle-Based Delivery System for Cancer and Neurodegenerative Disease Treatment (Deadline: 31 January 2025)
- Targeting the Lungs: The Potential of Aerosolized Medications in Gene Therapy (Deadline: 28 February 2025)
- Functional Polymers for Targeted Therapeutics and Gene Delivery (Deadline: 28 February 2025)
- Extracellular Vesicles for Cancer Therapy (Deadline: 28 February 2025)
- Nanotechnology and RNA-Based Technologies Applied to Prophylaxis and Advanced Therapies (Deadline: 10 March 2025)
- Cancer Gene Therapy with Non-Viral Nanocarriers, 2nd Edition (Deadline: 31 March 2025)
- Biomaterials and Delivery Systems for Regenerative Medicine (Deadline: 31 March 2025)
- Extracellular Matrix and Vesicles as Immunomodulatory Therapeutics (Deadline: 31 March 2025)
- Mesenchymal Stem Cell-Derived Extracellular Vesicles as Therapeutics, 2nd Edition (Deadline: 31 March 2025)
- Recent Advances in Adeno-Associated Virus-Mediated Gene Therapy and Vaccine Development (Deadline: 20 April 2025)
- Gene Therapy with LNPs, Possibilities, Limitations, New Strategies (Deadline: 30 April 2025)
- Trends in mRNA Vaccine Development and Applications (Deadline: 30 April 2025)
- Where Are We Now and Where Is Cell Therapy Headed? (Deadline: 20 May 2025)
- Gene Delivery Nanosystems (Deadline: 20 May 2025)
- New Strategies in Gene and Cell Therapy for Neurological Disorders (Deadline: 31 May 2025)
